T A B L E O F C O N T E N
Two RCTs supplied data on disability. In one RCT survival was low in both groups but none of the survivors had limitations in their daily activities six months after discharge. The other RCT reported improved survival without severe disability in the intervention group (transfer to an ECMO centre ± ECMO) six months after study randomization but no statistically significant differences in healthrelated quality of life.
In three RCTs, participants in the ECMO group received greater numbers of blood transfusions. One RCT recorded significantly more non-brain haemorrhage in the ECMO group. Another RCT reported two serious adverse events in the ECMO group, and another reported three adverse events in the ECMO group.
Clinical heterogeneity between studies prevented meta-analyses across outcomes. We found no completed RCT that had investigated ECMO in the context of cardiac failure or arrest. We found one ongoing RCT that examined patients with acute respiratory failure and two ongoing RCTs that included patients with acute cardiac failure (arrest).
Authors' conclusions
Extracorporeal membrane oxygenation remains a rescue therapy. Since the year 2000, patient treatment and practice with ECMO have considerably changed as the result of research findings and technological advancements over time. Over the past four decades, only four RCTs have been published that compared the intervention versus conventional treatment at the time of the study. Clinical heterogeneity across these published studies prevented pooling of data for a meta-analysis.
We recommend combining results of ongoing RCTs with results of trials conducted after the year 2000 if no significant shifts in technology or treatment occur. Until these new results become available, data on use of ECMO in patients with acute respiratory failure remain inconclusive. For patients with acute cardiac failure or arrest, outcomes of ongoing RCTs will assist clinicians in determining what role ECMO and ECPR can play in patient care. compared with those who were not. In one study survival was low in both groups but none of the patients who survived had limitations in their daily activities six months after discharge. Another study found improved survival without severe disability in patients transferred to an ECMO centre for consideration of ECMO six months after study entry. In three studies, patients in the ECMO group received greater numbers of blood transfusions. One study reported more non-brain bleeding in the ECMO group, and another study reported two serious adverse events in the ECMO group. Another study reported three adverse events in the ECMO group.
Quality of the evidence: Clinical practice, study planning and ways of using ECMO have varied considerably among studies. Technological developments (circuits, pumps and mechanical lungs) have improved performance and patient safety with ECMO applications over time. These clinical differences in the care provided for patients with acute lung failure prevented us from combining the results of individual studies. In critically ill adults, ECMO may or may not be more effective in improving survival compared with conventional lung support. Results from ongoing studies will help us better understand the role of ECMO and ECPR in the treatment of patients with acute lung or heart failure.
B A C K G R O U N D Description of the condition
Among critically ill adult patients, mortality rates are as high as 50% for those with acute cardiac failure and 30% to 40% for those diagnosed with severe respiratory failure (Douglas 2008) . Severe hypoxaemia and/or hypercapnia as a result of acute respiratory distress syndrome (ARDS), primary graft dysfunction following lung transplant and direct trauma are common conditions treated with respiratory extracorporeal membrane oxygenation (ECMO) support (Allen 2011). Acute respiratory distress syndrome is a potentially reversible clinical syndrome of lung inflammation caused by numerous direct and indirect lung insults (Brodie 2011). Pulmonary and extrapulmonary infection, aspiration and trauma are common causes of ARDS (Rubenfeld 2007) . Cardiogenic shock unresponsive to moderate-or high-dose inotropic support and refractory cardiac arrest are two clinical syndromes for which cardiac ECMO is used as rescue therapy (Chen 2008; Mirabel 2011) . Chronic cardiomyopathy, acute myocardial infarction, myocarditis, primary graft dysfunction following transplant, toxic/drug causes and pulmonary embolism are conditions that may result in cardiogenic shock or cardiac arrest (Allen 2011; Marasco 2008) . However, many patients have mixed conditions and die of sepsis or multi-organ failure (MOF) rather than from isolated respiratory or cardiac failure alone (Sidebotham 2009 ). When conventional treatment algorithms fail, ECMO may be a rescue therapy option for patients with severe failure of these organs (Marasco 2008) . Extracorporeal membrane oxygenation is well established as a treatment for infants with respiratory and cardiac failure, and evidence supports its use in adults with lifethreatening refractory hypoxaemia or hypercapnia, severely impaired cardiac pump function or both (Cooper 2007; Gattinoni 2011; Lindstrom 2009; Mugford 2008) . For example, guidelines on clinical triggers for initiation of ECMO in patients with respiratory failure include the following (ELSO 2014).
1. In hypoxic respiratory failure due to any cause (primary or secondary), extracorporeal life support (ECLS) should be considered when the risk of mortality is 50% (partial pressure of arterial oxygen for a given fraction of inspired oxygen (PaO 2 / FiO 2 ) < 150 mmHg on FiO 2 > 0.9; or Murray score 2 to 3 or greater) and is indicated when the risk of mortality is 80% or greater (80% mortality risk can be identified by a PaO 2 /FiO 2 < 80 mmHg on FiO 2 > 0.9; or Murray score 3 to 4).
2. Carbon dioxide (CO 2 ) retention due to asthma or permissive hypercapnia with PaCO 2 > 80 mmHg or inability to achieve safe inflation pressures (plateau pressure < 30 cm H 2 O) is an indication for ECLS.
3. Severe air leak syndromes are an indication for ECLS.
Description of the intervention
Extracorporeal membrane oxygenation is a form of extracorporeal life support that can provide complete (or partial) support of the heart and lungs (Sidebotham 2009). It consists of specialized cannulae that connect to the circulation, as well as circuit tubing, a membrane that oxygenates the blood and removes carbon dioxide and a blood pump that drives circuit blood flow (Douglas 2008). Current ECMO systems are rapidly deployable and mobile and can provide support over days to months (Forrest 2011). For patients with severe respiratory failure, ECMO accesses and returns blood from the venous system (veno-venous (VV) ECMO). It provides non-pulmonary gas exchange, facilitates protective lung ventilation and provides time for lung recovery from acute processes or bridging to lung transplant (Sorbo 2014). For those with severe cardiac failure or refractory cardiac arrest, ECMO provides systemic circulation (venous-arterial (VA) ECMO) and prevents further organ injury secondary to low blood flow (Allen 2011). This may allow time for cardiac recovery or bridging to longerterm cardiac support modalities. In contrast to these pump-driven ECMO circuits, other gas exchange systems are in clinical use. These pump-free systems provide mainly arteriovenous carbon dioxide elimination (pumpless arteriovenous extracorporeal CO 2 removal (avECCO 2 -R) or pumpless extracorporeal lung assist (PECLA) or interventional lung assist (iLA)) and use an arterovenous (AV) circuit in which blood flow through the artificial lung fully relies on native blood pressure, which limits gas exchange and its usage in critically ill patients (Bein 2006; Bein 2013; Sorbo 2014) . With pump-driven circuits, gas exchange rates and cardiac support depend on circuit configuration (VV or VA) and the flow of blood pumped through the artificial lung (normally 50 to 100 mL/kg/ min) (Park 2011 
How the intervention might work
Extracorporeal membrane oxygenation offers the possibility of supporting patients with life-threatening heart or lung conditions when conventional management is failing and thereby increases the time available to treat underlying illnesses (Gattinoni 2011) . During the course of ECMO, gas exchange does not depend on native lung function; this allows the lungs to rest while lung-protective mechanical ventilation strategies are used (Petrucci 2007). In VA ECMO, the extracorporeal circuit also provides cardiac support for patients who are unable to maintain sufficient cardiac output; this is seen in patients immediately after heart surgery or before or after heart transplantation (Chung 2010; D'Alessandro 2011; MacLaren 2012; Sidebotham 2009) . Recently, VA ECMO has been used to maintain cardiopulmonary circulation during advanced cardiac life support (extracorporeal cardiopulmonary resuscitation (ECPR)) (Chen 2008; Dalton 2011) . However, the primary indication for VA ECMO remains the patient's condition and not, for example, specific types of heart surgery for which circulation needs to be bridged as a requirement of surgery.
Why it is important to do this review
Use of ECMO in adults has been controversial since it was first successfully introduced as a treatment option for critically ill patients (Chalwin 2008 
O B J E C T I V E S
The primary objective of this systematic review was to determine whether use of VV or VA ECMO in adults is more effective in improving survival compared with conventional respiratory and cardiac support.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs that compared adult ECMO versus conventional support were eligible for inclusion in this review. Quasi-randomized controlled trials and cluster-randomized trials were also eligible for inclusion, although cross-over trials were not.
Types of participants
We included in this review all studies that included adult participants (18 years of age or older) with cardiac or respiratory failure, or both. We excluded all studies that included participants who underwent surgery for whom ECMO was established as a planned procedure for the purpose of surgery.
Types of interventions
We included in this review ECMO using pump-driven veno-venous (VV) and venous-arterial (VA) or pump-free arteriovenous (AV) circuits versus all forms of conventional management (e.g. intermittent positive-pressure ventilation). We excluded studies that compared other forms of mechanical support specifically designed to support heart function such as ventricular assist devices.
Types of outcome measures
Primary outcomes
1. The primary outcome of this review was rate of all-cause mortality closest to 30, 60 or 90 days and/or at six months.
Secondary outcomes
1. Length of hospital stay. 2. Survival to discharge. 3. Disability as reported by study authors. 4. Adverse outcomes. 5. Health-related quality of life, as reported by study authors. 6. Longer-term health status and well-being, as reported by study authors.
7. Cost-effectiveness. Outcomes did not form part of the study eligibility assessment, so studies that met participant, intervention and comparison criteria were included in the review even if they reported no relevant outcomes. 
Search methods for identification of studies

Searching other resources
We searched conference proceedings, meeting abstracts and databases of ongoing trials such as Current Controlled Trials (http://www.controlled-trials.com/) and Clinical Trials (http:// clinicaltrials.gov). The search was performed in August 2014. In January 2014, we contacted experts at specialized treatment centres in Australia, Brazil, Canada, France, Germany, New Zealand, the United Kingdom and the United States to request results from ongoing or completed research in this area.
Data collection and analysis
Selection of studies
Two review authors (RT, DI) independently screened the titles and abstracts of all retrieved citations against the inclusion criteria. On the basis of this approach, studies were categorized into two groups.
1. Possibly included (studies that met the inclusion criteria and warranted full-text access to gather further information).
2. Excluded (studies that clearly did not meet the inclusion criteria). RT and DI independently reviewed all full-text articles.
Data extraction and management
RT and DI independently used the modified data collection form of the Cochrane Anaesthesia Review Group (CARG) (Appendix 4) for data extraction from all included studies. This data extraction form includes information on sample participants (including demographic characteristics), study methods (setting, intervention, method of delivery) and reported results. All data from the included studies were extracted into Review Manager (RevMan 5.3). We resolved interrater differences by consensus and by discussion with three of the other review authors (AD, CH, VP).
Assessment of risk of bias in included studies
Two review authors (RT, DI) independently performed risk of bias assessment using the tool of The Cochrane Collaboration for assessing risk of bias (Higgins 2011). All included studies were appraised with respect to random sequence generation, allocation concealment, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Each of these criteria was assessed as having 'low risk of bias,' 'high risk of bias' or 'unclear risk of bias.' We considered a trial as having 'high risk of bias' if the domain 'random sequence generation' or 'allocation concealment' was assessed as inadequate or unclear. We included a 'Risk of bias' table as part of the Characteristics of included studies table and a 'Risk of bias summary' figure, which details all of the judgements made for all studies included in the review.
Measures of treatment effect
We transferred trial results using Review Manager (RevMan 5.3) and followed the recommendations given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We expressed dichotomous data (e.g. mortality) as risk ratios (RRs) with 95% confidence intervals (CIs). We used mean differences (MDs) or standardized mean differences (SMDs) with 95% CIs for continuous data (e.g. length of hospital stay).
Unit of analysis issues
We performed our analysis at the level of the individual.
Dealing with missing data
We contacted study authors in the event that not all relevant data were presented in the text of a study.
Assessment of heterogeneity
We noted clinical heterogeneity with respect to technical and medical advances in ECMO applications over the designated time period. We performed no assessment of statistical heterogeneity, as we conducted no meta-analyses.
Assessment of reporting biases
We did not test for publication bias by using a funnel plot or other similar analytical methods because fewer than 10 studies were included in this review.
Data synthesis
We decided not to proceed with meta-analyses in this review because of clinical heterogeneity observed between studies. In future versions of this review, we will revisit this decision as more trials are completed. We intend to use the following approach. We will analyse pooled results of continuous and dichotomous outcomes using an inverse variance random-effects or fixed-effect model, depending on the level of heterogeneity. We will use a randomeffects model in the event of moderate or high heterogeneity, and will apply a fixed-effect model in cases of low heterogeneity.
Subgroup analysis and investigation of heterogeneity
We planned to perform the following subgroup analyses if sufficient data were available (i.e. data from two or more studies). 
Sensitivity analysis
We did not perform a sensitivity analysis to identify the robustness of results with respect to sequence generation, concealment of allocation, blinding of outcome assessors and presence of missing data because no meta-analysis was performed.
Summary of findings
We planned to use the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system (Guyatt 2008) in our review to assess the quality of the body of evidence associated with specific outcomes of mortality, length of hospital stay, survival to discharge, disability, adverse outcomes, health-related quality of life, longer-term health status, well-being and cost-effectiveness, and to construct a standard 'Summary of findings' table. The GRADE approach is used to appraise the quality of a body of evidence on the basis of the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence reflects within-study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. We did not generate a standard 'Summary of findings' table because too few studies were available for inclusion. We summarized individual study outcomes in an additional table (Table 1 ) but did not use the GRADE system because no meta-analysis was performed. (Table 2 ). For further descriptive information about these studies, please refer to the Characteristics of included studies section.
R E S U L T S Description of studies
Excluded studies
We excluded eight studies because they were not randomized controlled trials. See Characteristics of excluded studies for further details.
Risk of bias in included studies
Assessment of risk of bias for each included study is described in the Characteristics of included studies section. Risk of bias was determined as follows for each included study.
1. Bein 2013: low risk of bias (half of domains were assessed as low risk; 'blinding of outcome assessment', 'incomplete outcome data' and 'selective reporting' were assessed as unclear risk).
2. Morris 1994: high risk of bias ('allocation of concealment', 'selective reporting' and 'other bias' were assessed as unclear risk; all other domains were assessed as low risk).
3. Peek 2009: low risk of bias (most domains were assessed as low risk; 'other bias' was assessed as unclear risk).
4. Zapol 1979: low risk of bias (half of domains were assessed as low risk; 'blinding of outcome assessment', 'selective reporting' and 'other bias' were assessed as unclear risk). Risk of bias is presented graphically in Figure 2 and Figure 3 . 
Allocation
Sequence generation and allocation concealment were clearly identified in three of the four studies (Bein 2013; Peek 2009; Zapol 1979) . One study (Morris 1994) did not provide an explicit statement with respect to how allocation was concealed.
Blinding
Blinding to the intervention was not possible. In one of the studies (Peek 2009), outcomes were assessed at six months by trained researchers blinded to the intervention, and participants covered their neck to mask cannulation status. Another trial (Zapol 1979) reported follow-up at six months with no information about blinding.
Incomplete outcome data
All studies reported the numbers of withdrawals and dropouts.
Selective reporting
In one of the studies (Peek 2009), risk of selective reporting was assessed as low. In the other trials (Bein 2013; Morris 1994; Zapol 1979) , risk was assessed as unclear.
Other potential sources of bias
Other bias was observed in three trials (Morris 1994; Peek 2009; Zapol 1979) . This related to variations in or absence of specific treatment and/or ventilation protocols in the intervention group and/or the control group during the study period. In one trial (Bein 2013), which hypothesized that mechanical ventilation using lower tidal volumes (3 mL/kg) assisted by avECCO 2 -R would enhance lung protection and increase ventilator-free days, the condition of 50 participants deteriorated during the screening phase; they were treated with VV ECMO, but no ECMO data or outcomes were reported. Three studies (Bein 2013; Peek 2009; Zapol 1979) were multi-centre trials; this contributed to performance bias in two trials (Peek 2009; Zapol 1979) .
Effects of interventions
A meta-analysis was not performed because of clinical heterogeneity noted across the included studies ( 
Length of hospital stay (LOS)
All RCTs but one (Zapol 1979) reported data on length of hospital stay (LOS). In one study (Morris 1994), LOS (days ± standard deviation (SD)) in the intervention group was 26.9 (± 4.9) compared with 28.8 (± 5.7) in the control group. The mean difference of 1.9 days was not significant (P value 0.09). In another study (Bein 2013), LOS was 46.7 (± 33) in the avECCO 2 -R group and 35.1 (± 17) in the control group. The mean difference of 11.6 days was not significant (P value 0.113). In one study (Peek 2009), participants in the intervention group had longer (median 18 days) LOS (days (interquartile range (IQR)) compared with participants in the control group (35 (15.6 to 74.0) vs 17.0 (4.8 to 45.3)).
Survival to discharge
Two RCTs reported data on survival to discharge (Bein 2013; Morris 1994) . One study (Morris 1994) reported survival at 30 days after randomization. In the intervention group, seven of 21 (33%) survived compared with eight of 19 (42%) in the control group. No differences were noted between groups (P value 0.8).
Another study (Bein 2013) found a non-significant survival to discharge rate of 33 of 40 (82.5%) in the intervention group compared with 33 of 39 (84.6%) in the control group (P value 1.00).
Disability as reported by study authors
Two studies (Peek 2009; Zapol 1979) supplied data on disability. One study (Zapol 1979) followed up on pulmonary function of survivors after discharge; for both groups combined (four participants in the intervention group and four in the control group), pulmonary function was normal in seven participants. No participants had limitations in their daily activities six months after discharge. The other study (Peek 2009) assessed "severe disability" at six months. Severe disability was determined by the first two items of the EQ-5D survey (standardized instrument from the EuroQoL Group used to measure health outcomes) (item Mobility = unable to walk around, in addition to item Personal Care = unable to wash or dress). A total of 63% (57/90) of participants allocated to consideration for treatment by ECMO survived to six months without severe disability compared with 47% (41/87) of those allocated to conventional management (RR 0.69, 95% CI 0.05 to 0.97; P value 0.03). Three participants in the control group had unknown disability status. Questions were answered by proxies for five participants in the intervention group and for seven in the control group.
Adverse outcomes
All RCTs provided data on adverse outcomes. In one study (Zapol 1979) , adverse outcomes including septicaemia (20%) and pneumothorax (45%) were similar in both groups. Participants in the intervention group had lower blood platelet and white blood cell concentrations and greater blood/plasma infusion (reported at 1 to 2.5 L/d). In another study (Morris 1994), recorded major complications other than organ failure were divided into central nervous system (CNS), peripheral vascular system and other. Investigators noted 34 major complications in the intervention group and 16 in the control group, but the overall difference was not statistically significant (P value 0.12). However, non-CNS haemorrhage occurred significantly more often (21 vs 0) in the intervention group, and transfusion of packed red blood cells (RBCs) exceeded 0.8 L/d in 10 participants, leading to bypass disconnection in seven participants in the intervention group. Another study (Peek 2009) reported two serious adverse events in the intervention group and none in the control group. One was death due to mechanical failure of oxygen supply during ambulance transport. Vessel perforation during cannulation was the other serious adverse event; however, this did not result in death of the participant. The latest study (Bein 2013) reported adverse outcomes in three participants (7.5%). One had transient ischaemia of the lower limb, and two developed a "false" aneurysm from arterial cannulation. Study authors reported significantly higher transfusion of RBCs during the time between randomization and day 10 in the intervention group when compared with the control group (3.7 ± 2.4 vs 1.5 ± 1.3 units RBCs; P value < 0.05).
Health-related quality of life One study (Peek 2009 ) reported data on health-related quality of life using the Short Form (SF)-36 and EQ-5D surveys. Study authors reported no differences between intervention and control groups when EQ-5D data or any other follow-up assessments were compared at six months. For 17 participants EQ-5D data were missing.
Longer-term health status and well-being
No RCTs provided data on longer-term health status and wellbeing. 
Cost-effectiveness
D I S C U S S I O N Summary of main results
A limited number of studies on this topic have been published. We included in this systematic review four randomized controlled trials (RCTs) that met our inclusion criteria to evaluate extracorporeal membrane oxygenation (ECMO) for critically ill adults. 
Quality of the evidence
The quality of the evidence was assessed using the approach outlined in Characteristics of included studies. The body of evidence was classified as having 'high,' 'low,' or 'unclear' risk of bias for each outcome. Overall, the evidence was assessed as having 'low' risk of bias. ). In the latest RCT (Bein 2013), mortality rate was not a primary outcome because researchers investigated the effects of combining a very low tidal volume (3 mL/kg) with avECCO2-R in established ARDS compared with standard mechanical ventilation (6 mg/kg). Randomization occurred after a 24-hour stabilization phase, and a total of 226 participants who were screened during this phase were excluded. The condition of 50 of these participants deteriorated, and they were treated with VV ECMO, but no data or outcomes have yet been reported. The newer trials also used different applications of the intervention (VV ECMO vs avECCO 2 -R), leading to exclusion of aggregated data.
Evidence from observational studies suggests improved outcomes of ECPR compared with CPR in patients with acute cardiac failure, but no completed RCT has yet been published.
Potential biases in the review process
This review consisted of published data. Future versions of this review will include further details on primary and secondary outcomes as they become available through continuing publication of included studies and studies that have been identified as in progress. The review authors concluded that the benefit of ECMO for hospital mortality was unclear. Our group previously assessed the evidence with respect to H1N1 influenza-related acute respiratory failure and came to the same conclusion (Cooper 2013). The systematic review of Zangrillo et al (Zangrillo 2013) also focused on patients with H1N1 influenza and included results from eight observational studies with 266 participants. These review authors included in their quantitative analysis one study previously discussed (Noah 2011). Using random-effects aggregated estimates and noting considerable heterogeneity, the review authors reported overall in-hospital mortality of 27.5% (95% CI 18.4% to 36.7%) and noted that exploratory meta-regression did not identify any significant moderator of mortality. From the results, the review authors concluded that ECMO is feasible and effective in patients with respiratory failure due to H1N1 infection. They also conducted a meta-analysis of complications and mortality in VV and VA ECMO populations (Zangrillo 2013a). These review authors included 12 studies that reported mortality data from registries with more than 100 participants and included only studies that also described fatal and non-fatal complications in detail. Overall mortality was 54% (95% CI 47% to 61%) after a median follow-up of 30 days. None of the trials included in our review was included in the meta-analysis. Fitzgerald et al (Fitzgerald 2014) collated evidence from 14 trials including two RCTs included in this review (Bein 2013; Morris 1994) and assessed the effects of VV and AV ECCO 2 -R on mortality. The review authors concluded that available evidence suggested no mortality benefit of ECCO 2 -R. However, they noted that ECCO 2 -R technology is rapidly evolving and is effective in enabling protective lung ventilation (Fitzgerald 2014). Munshi et al (Munshi 2014) included in their systematic review (the latest) all four studies that form part of this review and added to their meta-analysis six other observational studies (including Noah 2011 and Pham 2012) .These review authors found no association of a mortality benefit for ECLS but reported a mortality benefit when the meta-analysis was restricted to higher-quality studies of VV ECLS. Our review suggests that more data from RCTs are needed before meta-analysis of trials can be performed and recommendations can be made regarding the effectiveness of ECMO in reducing overall mortality.
Agreements and disagreements with other studies or reviews
A U T H O R S ' C O N C L U S I O N S Implications for practice
Extracorporeal membrane oxygenation remains a rescue therapy for critically ill adult patients. Over the past four decades, only four RCTs published results that compared the intervention versus conventional treatment at the time of the study. All studies comprised participants with acute respiratory failure. 
Implications for research
Results from ongoing research studies (NCT01470703) will further clarify the benefit or harm of ECMO for critically ill adults with acute respiratory failure. Current research into mortality risk prediction in this complex patient cohort will help clinicians more clearly identify patients who may benefit from the intervention in the future (Brogan 2009; Pappalardo 2013; Schmidt 2013; Schmidt 2014) . Protective mechanical lung ventilation is permitted by VV and AV ECCO 2 -R, and future trials such as SUPER-NOVA (Strategy of UltraProtective lung ventilation with Extracorporeal CO 2 Removal for New-Onset moderate to seVere ARDS) will validate the benefit of these non-full-flow ECMO approaches in the treatment of patients with acute respiratory failure (Terragni 2014).
Ongoing and planned RCTs will clarify the role of ECMO and ECPR in patients with acute cardiac failure (NCT01511666; NCT01605409). We have noted that indications and applications of the intervention are much broader than they used to be. Future systematic reviews must account for this diversity in their search strategies and analyses.
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R E F E R E N C E S
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Bein 2013
Methods
This multi-centre randomized clinical trial conducted in Germany (8 sites) and Austria (2 sites) hypothesized that mechanical ventilation using lower tidal volumes (3 mL/kg) assisted by avECCO 2 -R would enhance lung protection and hence increase 28-day and 60-day ventilator-free days compared with mechanical ventilation using conventional tidal volumes (6 mL/kg) After screening for inclusion of patients with a PaO 2 /FiO 2 ratio ≤ 200 mmHg, eligible patients entered a 24-hour stabilization phase with the following targets: VT 6 mL/kg/ IBW; "high peep" as per ARDSNet, CVP 10 to 16 mmHg; MAP ≥ 70 mmHg and haemodynamic evaluation via echocardiography Participants who remained with a PaO 2 /FiO 2 ≤ 200 mmHg were randomly assigned via phone using a random number table generated by the involved statistician. Researchers assessed ventilator-free days at 28 and 60 days, non-pulmonary organ failure-free days at 60 days, lung injury score at day 10, length of hospital/ICU stay and in-hospital mortality
Participants
Patients with ARDS according to the American-European Consensus Conference in intensive care units (ICUs) in Germany and in Austria Inclusion criteria: ARDS according to the American-European Consensus Conference with bilateral infiltrates on chest x-ray and PaO 2 /FiO 2 < 200 mmHg for at least 2 hours. Screening exclusion criteria: left ventricular failure; age > 18 years; history of mechanical ventilation > 7 days; plateau pressure > 25 cm H 2 O at defined ventilator settings (PEEP/ FiO 2 -table + VT = 6 mL/kg) and absence of severe haemodynamic instability with high demand for vasopressors (MAP ≥70 mmHg with continuous norepinephrine infusion < 0.4 mcg/kg/min) Exclusion criteria: decompensated heart insufficiency, acute coronary syndrome, severe chronic obstructive pulmonary disease, advanced malignancy with life expectancy < 6 months, long-term dialysis treatment, lung transplant, proven heparin-induced thrombocytopenia (HIT), morbid obesity (BMI 40 kg/m 2 ), cirrhosis of the liver, Child class ≥ B (Child-Pugh scores > 7) or acute fulminant hepatic failure, severe peripheral arterial occlusive disease, absence of limb doppler pulse and acute brain injury (Glasgow Coma Scale < 9). Of 79 randomly assigned participants, 40 were assigned to the intervention group (avECCO-R) and 39 to the control group
Interventions
The 40 participants in the intervention group received percutaneous cannulation and initiation of pumpless extracorporeal lung assist (iLA AV; Novalung, Heilbronn, Germany). Unlike "classic" pump-driven extracorporeal carbon dioxide removal, iLA does not require a blood pump because the extremely low resistance of this circuit allows flows of about 1 to 2 L/min with normal arterial pressures. After initiation of avECCO 2 -R, the ventilation strategy according to study protocol was adapted as follows: rapid titration down to VT 3 mL/kg/PBW, PEEP following ARDSNet "high-PEEP/FiO 2 " table, respiratory rate 10 to 25/min with an inspiratory/expiratory ratio of 1:1. Termination of avECCO 2 -R therapy and decannulation were performed according to a defined algorithm The 39 participants in the control group received ventilatory management that followed Bein 2013 (Continued) the algorithm of the study group except for the use of VT = 6 mL/kg/PBW. Target blood gases for both groups were as follows: PaO 2 > 60 mmHg and arterial pH > 7.2. Use of buffering (tris-(hydroxymethyl) aminomethane (TRIS)) was permitted if the participant had hypercapnia and respiratory acidosis (pH < 7.2)
Outcomes
The primary outcome parameter was the proportion of days without assisted ventilation in a 28-day period ("ventilator-free" days within 28 days (28-VFD)) and in a 60-day period ("ventilator-free" days within 60 days (60-VFD)) Secondary outcomes included inspiratory plateau pressure levels (Pplat), proportion of spontaneous breathing as a percentage of the minute ventilation (automatically calculated by the ventilator's software), RASS score, haemodynamic changes, incidence of complications or adverse reactions, frequency and duration of other adjunctive therapeutic measures, transfusion requirements (packed red blood cell transfusions (units), fresh frozen plasma units, platelet transfusion), daily cumulative doses of analgesic and sedative agents, cumulative catecholamine requirements/24 h throughout the study period, frequency and duration of renal replacement therapy, number of failing organs, "organ-failure-free days" within 28 days after randomization and "in-hospital" mortality Notes Screening was followed by a stabilization period of 24 hours, characterized by lung-protective mechanical ventilation with high PEEP (≥ 12 cm H 2 O), use of supportive measures and haemodynamic evaluation (echocardiography). Participants who met ARDS criteria (PaO 2 /FiO 2 < 200 mmHg) after 24 hours despite optimal supportive treatment were identified as those with established ARDS and were randomly assigned. 50 participants were excluded and were treated with VV ECMO This study was supported by a grant from Novalung, Heilbronn, Germany
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk "Randomized through phone hot line by a random number table generated by the involved statistician"
Allocation concealment (selection bias) Low risk "Randomized through phone...by the involved statistician with respect to the stratum pulmonary/non-pulmonary ARDS"
Blinding of outcome assessment (detection bias) All outcomes
Unclear risk "At the time of screening (24 hr prior to randomization) physiologic data were recorded and relevant laboratory, radiographic and clinical findings were collected. Throughout the complete study period, data on ventilator settings, laboratory, physiologic, radiographic and interventional data were recorded" Patients with ARDS. ARDS was defined by the presence of all of the following: P(a/A) O 2 < 0.2, bilateral chest radiographic infiltrates, CTH < 50 mL/cm H 2 O and PW < 15 mmHg (or no clinical evidence of heart failure). Patients with severe ARDS who met ECMO entry and exclusion criteria were considered candidates for the clinical trial 249 patients with ARDS were identified, and 41 met ECMO entry criteria. 40 participants were enrolled (1 with no consent) and were randomly assigned from August 25, 1987 , to April 24, 1991 . Of these 40 randomly assigned participants, 5 were originally admitted to the LDS Hospital and 35 were transferred there from other hospitals: 6 from Salt Lake City hospitals, 6 from Utah hospitals outside Salt Lake City and 23 by air from out-of-state hospitals. Patient referrals were actively solicited from within the LDS Hospital and from other medical centres. All patients at the LDS Hospital were screened for ARDS
Interventions
Researchers constructed an extracorporeal system with a parallel and series configuration of two 3.5-m 2 Sci-Med membrane lungs for gas and blood flow, respectively. If PCIRV support failed, LFPPV-ECCO 2 R was initiated. Failure of PCIRV was based on failure to maintain PaO 2 or failure to maintain pHa. 21 participants received the intervention (LFPPV-ECCO 2 R). 3 to 6 hours after initiation of LFPPV-ECCO 2 R, the Ppeak was 45. Low risk "Blinded randomization with blocking was used, and patients were assigned to receive either control therapy or the new therapy"
Allocation concealment (selection bias) Unclear risk "Blinded randomization with blocking was used, and patients were assigned to receive either control therapy or the new therapy"
Low risk Blinding of outcome assessment was not reported. However, it was judged unlikely that outcome assessment was influenced by lack of blinding: "The end point of this analysis was the time until death occurred"
Incomplete outcome data (attrition bias) All outcomes
Low risk "We randomized all patients who met entry criteria, despite the gravity of their clinical state (1 new therapy patient died rapidly before we could initiate LFPPV-ECCO 2 R, and 2 patients died within 1 day after initiating LFPPV-ECCO 2 R). We observed the "intention-to-treat" principle in our eval-uation of this new therapy in the clinical trial"
Selective reporting (reporting bias) Unclear risk Information was insufficient to permit a judgement
Other bias Unclear risk "We used a minimum VT of 4 ± 0.5 ml/kg BWp rather than a Ppeak limit. We abandoned use of the Ppeak limit because of difficulty in maintaining a VT > 100 ml in some patients after several days of extracorporeal support. After the first 10 patients, we were advised to insist upon a minimum VT of about 250 ml (A. Pesenti, personal communication). Of 6 survivors receiving LFPPV-ECCO 2 R, 3 were maintained with the Ppeak limit and 3 with the minimum VT after we abandoned the Ppeak limit" "We used explicit protocols to ensure uniformity of care, with equal frequency of monitoring, consistent decision-making logic for the management of arterial oxygenation, and common PaO end points for all randomized ARDS patients from the time of randomization to extubation or death, regardless of the therapy limb"
Peek 2009
Methods This multi-centre randomized clinical trial aimed to delineate the safety, clinical efficacy and cost-effectiveness of extracorporeal membrane oxygenation (ECMO) compared with conventional ventilation support Participants 180 participants were enrolled from 3 types of centres: the ECMO Centre at Glenfield Hospital, Leicester, which treated all patients who were randomly allocated for consideration to receive ECMO; tertiary intensive care units (conventional treatment centres) ; and referral hospitals, which sent patients to conventional treatment centres if they were randomly allocated to receive continued conventional management. 103 hospitals obtained ethics committee approval to collaborate in the study, of which 92 were conventional treatment centres and 11 were referral hospitals Eligible patients were aged 18 to 65 years with severe but potentially reversible respiratory failure and a Murray score (from all 4 variables-PaO 2 /FiO 2 ratio, positive end-expiratory pressure, lung compliance and chest radiograph appearance-and FiO 2 1) of 3.0 or higher, or uncompensated hypercapnia with pH < 7.20 despite optimal conventional treatment. Reversibility was based on the clinical opinion of 1 of 3 duty ECMO consultants. Patients were also considered for inclusion if the Murray score was 2.5 or higher, so that trial entry could be accelerated if the condition of the patient continued to deteriorate Patients were excluded if they had been on high-pressure (peak inspiratory pressure > 30 ECMO was continued until lung recovery, or until apparently irreversible multi-organ failure Participants randomly allocated to receive conventional management were given the best critical care practice available at their conventional treatment centres. As a pragmatic trial, a specific management protocol was not mandated, but treatment centres were advised to follow a low-volume low-pressure ventilation strategy-i.e. tidal volume of 4 to 8 mL/kg body weight and pressure plateau < 30 cm H 2 O.
Outcomes
Primary outcome: death or severe disability at 6 months after randomization (defined as death by 6 months or before discharge from hospital at any time to the end of data collection) Severe disability was defined as confinement to bed and inability to wash or dress alone; according to this definition, all patients were severely disabled at randomization. Health status at 6 months after randomization was assessed from activities of daily living Patients were excluded from the study if any of the following criteria were applicable: age < 12 or > 65 years; duration of pulmonary insult > 21 days; pulmonary capillary wedge pressure > 25 mmHg; chronic systemic disease, including irreversible CNS injury, chronic pulmonary disease, rapidly fatal malignancy and chronic heart, liver or renal failure; severe body burns; or lack of physician or patient consent Interventions For 42 participants, veno-arterial partial bypass was performed at the 9 centres using 4 membrane oxygenator designs (Kolobow Scimed, Lande-Edwards, Bramson and General Electric Peirce). Venous blood was roller-pumped through the membrane oxygenator and was returned to the systemic circulation. All bypass participants received intravenous heparin, and their kaolin-activated coagulation time was monitored at least hourly. To assess changes in pulmonary haemodynamics, 45 participants had a flow-directed pul-Zapol 1979 (Continued) monary artery catheter inserted. When possible, bypass flow was reduced to 0.5 L/min every 12 hours and arterial blood gas tensions were sampled without substantial extracorporeal support 48 participants in the control group were treated with conventional mechanical ventilation Outcomes Survival.
Notes
This study was supported by the Division of Lung Diseases, National Heart, Lung and Blood Institute
Risk of bias
Bias
Authors' judgement Support for judgement
Low risk "Therapy, either mechanical ventilation alone (control) or supplemented with partial bypass, was randomly assigned by the data centre after entry into the study"
Allocation concealment (selection bias) Low risk "…randomly assigned by the data centre after entry into the study" 
Characteristics of excluded studies
S O U R C E S O F S U P P O R T Internal sources
• Monash University, Australia. RT is supported by an Australian Postgraduate Award (APA) administered by the University. In kind support of infrastructure and database access.
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